Deals In Depth: June/July 2014
For $635 million, Baxter acquired two marketed infectious vaccines from Pfizer; after five offers, Shire accepted AbbVie’s bid for $53.3 billion. Biopharma firms raised a total of $5.7 billion in June and July, while device companies raked in $924 million.
You may also be interested in...
FDA Sunsets VCRP, Will Launch New Portal For Mandatory Cosmetics Registration Under MoCRA
FDA is closing down its 50-year-old Voluntary Cosmetic Registration Program as it prepares a new portal for facility registration and product/ingredient listing under the Modernization of Cosmetic Regulations Act. The Independent Beauty Association says the news marked an important step, but dismayed many stakeholders who hoped VCRP data would transfer to the new system or otherwise be preserved.
Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy
Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.
Pipeline Watch - ADD Meeting Dominates Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.